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Pre-retrieval reperfusion decreases cancer recurrence
after rat ischemic liver graft transplantation
to increase the yield of transplantable livers from this source
for HCC candidates awaiting liver transplantation.
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Letters to the EditorTo the Editor:
We read with great interest the article ‘‘Pre-retrieval reperfusion
decreases cancer recurrence after rat ischemic liver graft
transplantation’’ [1]. This elegant study assessed the impact of
ischemic liver graft on the risk of cancer recurrence utilizing a
rat liver transplantation model. Oldani et al. [1] demonstrated
that ischemia/reperfusion lesions lead to an increased risk of
post-transplant hepatocellular carcinoma (HCC) recurrence and
growth, which can be reversed by graft reperfusion prior to
retrieval. However, in this study, they clamped the vena porta
and infra-hepatic vena cava during 10 or 30 min prior to ﬂushing
and retrieving the liver to simulate the ischemic donors, and the
liver was reperfused for two hours after all clamps were removed
at the end of the clamping to simulate ischemic/reperfused
donors. Apparently, the quality of blood reperfused in this
transplantation model is better than the perfusion solution used
during normothermic extracorporeal membrane oxygenation
(NECMO) after circulatory death in clinical situations to some
extent [2]. Thus, we wonder if the risks of post-transplant cancer
recurrence can be reduced by graft reperfusion with ‘‘perfusion
solution’’ used in clinical prior to retrieval?
In addition in a further study, it is necessary to estimate the
combined feasibility and availability of pre-retrieval reperfusion
with different NECMO time with the aim to reduce the risk of
cancer recurrence and to repair and resuscitate the liver grafts
from donation after cardiac death (DCD) donors. This may helpReply to: ‘‘Pre-retrieval reperfusion decreases cancer recurrence after
rat ischemic liver graft transplantation’’
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Open access under CC BY-NC-ND license.resonance imaging. A two-hour donor liver reperfusion prior to
retrieval was reversing the effects of ischemia/reperfusion and
was associated to lower rates of post-transplant HCC growth.
Normothermic extracorporeal membrane oxygenation (NEC-
MO) is the closest clinical procedure to reproduce the studied
model, as it allows restoring the perfusion of the donor organs
in case of donation after cardiac death (DCD). Apart from being
primed with a perfusion solution, NECMO uses the donor’s own
blood, with a maintained pH between 7.0 and 7.4 [3]. However,
it is currently unknown whether NECMO can also have a protec-
tive impact on post-transplant HCC recurrence/growth, and thisTo the Editor:
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gesting an increased rate of hepatocellular carcinoma (HCC)
recurrence/growth after transplantation of ischemic liver grafts,
and the protective effect of in situ graft reperfusion prior to
retrieval [2].
Our rat transplantation model only approximates clinical real-
ity. It used liver grafts undergoing 10 or 30 min of ischemia prior
to retrieval (clamping the porta hepatis and the infra-hepatic
vena cava in the donor). HCC cells were injected intra-portally,
and liver HCC volumes were repeatedly assessed by magnetic2014 vol. 61 j 962–966
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ﬁeld deserves further assessment. Similarly, ex situ machine per-
fusion, either normothermic, hypothermic or sub-normothermic
has conﬁrmed protective effects on liver ischemia/reperfusion
lesions, but its impact on cancer has never been tested [4–8].
The minimal required time of liver graft reperfusion for pre-
venting HCC growth is currently unknown. The used two-hour
reperfusion matches international reports with NECMO or ex situ
machine perfusion ranging between one and four hours [3,7,8]. It
is also in agreement with the need for a minimal two-hour graft
normothermic machine reperfusion in order to restore the
function of ischemic rat livers [4].
Overall, ischemia/reperfusion may be an added factor altering
post-transplant cancer recurrence. This link is likely weaker
than the one between pre-transplant HCC characteristics and
recurrence, but it deserves further exploration both to better
understand the underlying mechanisms and the ways to prevent it.Conﬂict of interest
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Incidence of anti-HLA donor speciﬁc antibodies in liver-transplant
patients given mTOR inhibitors without calcineurin inhibitorsTo the Editor:
After liver transplantation (LT), immunosuppression with mam-
malian target-of-rapamycin (mTOR) inhibitors without calcineu-
rin inhibitors (CNIs) is used to preserve kidney function [1], and
because of its anti-neoplastic effect, particularly for patients
who have a history of hepatocellular carcinoma [2]. However,
in kidney-transplant patients, this immunosuppressive strategy
has been associated with an increased risk of developing donor-
speciﬁc antibodies (DSAs) [3]. After a LT, although the impact of
the occurrence of de novo DSAs on short- and long-term out-
comes is still controversial [4], de novo DSAs are associated with
an increased risk of antibody-mediated rejection [5], chronic
rejection [6–8], and anastomotic biliary stricture [9]. However,
because the incidence of de novo DSAs using the Luminex assay
in liver-transplant patients receiving mTOR inhibitor-basedJournal of Hepatology 20immunosuppression is unknown, this was the aim of this retro-
spective study.
Between 2008 and 2013, 394 liver-transplant patients were
followed-up in our institution. Of these, 61 patients were receiv-
ing an mTOR inhibitor (6.5%). Five of the 61 patients were
excluded from the study: four because they had not undergone
anti-HLA screening after conversion to mTOR inhibitors, and
one patient because he received both CNIs and mTOR inhibitors.
Hence, 56 liver-transplant patients, converted from CNIs to mTOR
inhibitors, were included in this study (Table 1). Twelve patients
had undergone an abrupt conversion from CNIs to sirolimus and
44 patients had undergone progressive conversion to everolimus.
The target trough (C0) levels for sirolimus and everolimus were
6–10 ng/ml. The median time between conversion to mTOR
inhibitors and the last follow-up was 28 (range: 2–102) months.14 vol. 61 j 962–966 963
